SlideShare a Scribd company logo
1 of 8
Download to read offline
GlaxoSmithKline's (GSK) $3 Billion Whistleblower
Settlement Has Paid for One Of America's Most Expensive
Failed Corporate Internal Investigations, Qui Tam
Whistleblowers' Attorneys Say.
The
original Complaint is one of the first ever filed alleging prescription
drug off-label promotion, Kenney said.
When the whistleblowers' Complaints were still under seal and
being investigated by the government GSK allegedly falsified and
concealed documents in connection with an FDA inquiry into whether GSK
marketed the antidepressant drug Wellbutrin off-label for weight loss, a
central allegation in the whistleblowers' Complaints. Massachusetts Assistant
Attorney General Bob Patten led the investigation on behalf of the
states and the National Association of Medicaid Fraud Control Units
("NAMFCU").
Case Caption: United States ex rel. Generally, government-funded healthcare programs such as
Medicare and Medicaid preclude reimbursement for off-label
prescriptions. Department of
Justice, and the U.S. An ensuing GSK internal
investigation verified their allegations, but the company took no
action, choosing hefty profits over compliance and patient safety,"
said whistleblower attorney Tavy Deming of Kenney McCafferty.
"GSK could have saved hundreds of millions, perhaps a billion
or more dollars of the $3 billion it paid today by following through on
the combined Human Resources /Corporate Compliance investigation they
launched. As a result,
Advair's portion of taxpayers' recovery represents nearly 70
percent of the Government's total $1.017 billion civil settlement
of our clients' claims, Lambert added.
The nine prescription drugs covered by the settlement included
Advair, Wellbutrin, Paxil, Lamictal, Zofran, Imitrex, Lotronex, Flovent
and Valtrex.
GSK maintained an elaborate illegal marketing regime for the
prescription drugs included in today's settlement, including,
according to filed documents:
* Paying physicians (who could be counted on to influence their
peers) as much as $25,000 for being a GSK "advisory board"
member;
* Enrolling 49,000 physicians and health professionals to be part of
its speakers bureau;
* Identifying physicians in academia to pay to speak on behalf of
one of the company's drugs;
* Creating the PowerPoint "slide kits" that physicians
would use to deliver canned presentations;
* Using an elaborate "FaxBack" system allowing drug
marketing reps to suggest articles related to off-label uses. No.: 11-10398 (D.Mass)
About Kenney McCafferty, P.C.:
Kenney McCafferty, P.C. is the one of the most successful
national law firms specializing in representing qui tam, tax, and SEC
whistleblowers. When the two
Kenney McCafferty-represented whistleblowers reported their
concerns about illegal marketing practices they were witnessing in the
field, GSK's top compliance executive, an attorney who now holds a
similar position with another medical device manufacturer, became
involved in and oversaw the ensuing internal investigation.
Instead of changing the illegal conduct, the Company retaliated
against the whistleblowers and they became the first to file an
off-label marketing qui tam whistleblower Complaint against GSK. Federal laws also prohibit
pharmaceutical companies from paying kickbacks to physicians to induce
prescriptions. "It's been a very, very, very long 10
years for whistleblowers Thorpe and Blair Hamrick."
GSK's top management was aware of illegal marketing schemes
involving the drugs, according to filed court documents. (U.S. In turn, as is typical in civil
agreements, GSK expressly
denied liability, except for those admissions GSK agreed to make in
connection with connection with a criminal Plea Agreement. v. Our clients properly reported those
marketing misdeeds to management in 2001. The
physicians would order these -off-label promotional materials by calling
a toll-free number, and thus not appear to be responding to an illegal
marketing effort by the drug marketing representative;
* Pushing Imitrex, an adult medicine for migraine, for mild
headaches, as well as for use in children, despite the FDA's
rejection of GSK's application for child use due to lack of
efficacy;
* Pushing Lamictal, a drug approved only for partial seizures, in
adults for other diagnoses. Instead they ignored evidence of improper marketing and
physician kickbacks. In at least one case a patient died from a
reaction that the company had evidence could occur;
* Marketing Paxil, the antidepressant, to children under 18 when it
had not been approved for youngsters, and despite GSK's own
clinical trails that had shown that the drug was ineffective for
children and also heightened the risk of suicide or other self-harming
behavior three-fold; and,
* Marketing the antidepressant Wellbutrin as superior to other
antidepressant alternatives due to increased sexual functioning and
weight loss, pushing the drug as the "happy, horny, skinny
drug," to concisely encapsulate GSK's off-label Wellbutrin
marketing campaign.
Physicians are free to prescribe drugs for off-label uses, but
pharmaceutical companies are prohibited from marketing the drugs for
uses that have not been approved by the FDA. Lauren Stevens, District
of Maryland)
Thorpe and Hamrick provided first-hand revelations of GSK's
pervasive marketing misconduct relating to the nine drugs identified in
Kenney McCafferty's Complaint (See "Document Links"
Below) and Exhibits (See "Document Links" Below) unsealed with
today's settlement. Kenney McCafferty's qui tam lawsuits have
resulted in cases in which more than $5 billion in civil and criminal
fines and penalties have been recovered for federal and state
Governments, resulting in the payment of hundreds of millions of dollars
in whistleblower rewards.
Contacts: Kenney McCafferty, P.C. 215-367-4333
Brian Kenney bkenney@kenneymccafferty.com Tavy Deming
tdeming@kenneymccafferty.com.
Additional information about the firm is available at
http://www.quitam-lawyer.com and http://www.tax-fraud.net.
Document Links:
Call the attorneys to obtain at-once copies of these documents. For
not-breaking access, as they become available, filed documents can be
accessed via the "GSK" link on the quitam-lawyer.com homepage
"Cases Over $100 Million."
SOURCE Kenney McCafferty, P.C.
COPYRIGHT 2012 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the
copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.
. When you look at the detail and accuracy of Greg
Thorpe's written complaints distributed to the highest levels of
Glaxo (See 'Document Links' Below) it's almost surreal
that the company took no corrective action. Now more than a decade
later, GSK is essentially admitting that Thorpe had been right in
2001," Kenney said. That led to
the indictment of a GSK associate corporate counsel, said Deming.
Federal charges against the former associate general counsel later were
subsequently dismissed by the court. His law firm, Kenny McCafferty, P.C., represents the two
whistleblowers who sparked the nine-year federal probe that ended with
today's $3 billion payment to settle off-label drug marketing
allegations involving nine prescription drugs.
"When our clients were forced out of their marketing positions,
GlaxoSmithKline ('GSK') had proof of illegal off-label
prescription drug marketing. The FCA allows the Government to collect up to three
times the amount it was defrauded, in addition to civil penalties from
$5,500 to $11,000 per false claim.
In successful qui tam whistleblower cases in which the Government
intervenes, whistleblowers are entitled to receive a percentage of qui
tam recoveries, typically 15-to-25 percent, generally known as,
"the relator's share."
Under the terms of the settlement agreement, the Government and the
whistleblowers did not http://www.schmidtlaw.com/zofran-lawsuits/ concede that their respective
claims are not well
founded. (See "Document Links" Below)
Extremely persuasive proof exposing illegal marketing of the asthma
drug Advair for mild asthma was included in the insider evidence that
Thorpe and Hamrick provided to Government investigators, Deming said.
GSK's mild asthma marketing campaign contravened Advair's
approved asthma use, which was limited to moderate and severe forms of
asthma, and a black box warning on the zofran birth defects heart drug's label, yet GSK's
marketing efforts continued unabated into 2010. v. According to Emily Lambert of Kenney 
McCafferty, the Government joined the whistleblowers' case and
filed a Complaint-in-Intervention adopting the whistleblower's
claims. Attorney's Offices for the District of
Massachusetts and the District of Colorado. Thorpe, et al. When a pharmaceutical company's illegal
marketing
practices cause off-label prescriptions to be written by doctors, and
those prescriptions are paid for by Medicare and Medicaid, the payment
becomes an actionable False Claims Act ("FCA") violation,
according to Kenney, who is a former federal prosecutor.
Under the FCA, qui tam actions allow private citizens with knowledge
of fraud to help the Government recover ill-gotten gains and additional
civil penalties. Specifically,
according to the agreement, GSK has agreed to plead guilty to criminal
charges that the company misbranded Wellbutrin and Paxil and it failed
to report data relating to clinical experience, along with other data
and information regarding the diabetes drug Avandia to the Food and Drug
Administration ("FDA") in mandatory reports, all in violation
of the Food, Drug and Cosmetic Act ("FDCA").
In addition to paying a $1.042 billion civil settlement to the
federal and state Governments, as part of the Settlement Agreement GSK
agreed to be bound by a Corporate Integrity Agreement ("CIA")
with the Office of Inspector General of the United States Department of
Health and Human Services ("OIG-HHS").
The federal investigation into GSK's marketing practices was
conducted through a collaborative effort of the U.S.
PHILADELPHIA, July 2, 2012 /PRNewswire/ -- GlaxoSmithKline has just
paid for one of the most expensive failed internal investigations in
corporate history, qui tam whistleblower attorney Brian Kenney said
today. GSK, et
al.Civ

More Related Content

What's hot

MNK Employees vs. Company 9/6/2017 Lawsuit
MNK Employees vs. Company 9/6/2017 LawsuitMNK Employees vs. Company 9/6/2017 Lawsuit
MNK Employees vs. Company 9/6/2017 Lawsuitquoththeraven
 
DEA Hit with Another Cannabis Lawsuit
DEA Hit with Another Cannabis LawsuitDEA Hit with Another Cannabis Lawsuit
DEA Hit with Another Cannabis LawsuitCannabis News
 
CannLabs presentation from WeedStock Investor Conference 2014
CannLabs presentation from WeedStock Investor Conference 2014CannLabs presentation from WeedStock Investor Conference 2014
CannLabs presentation from WeedStock Investor Conference 2014CannLabs
 
California's marijuana industry under attack
California's marijuana industry under attackCalifornia's marijuana industry under attack
California's marijuana industry under attacknaiveinstinct1140
 
California's marijuana industry under attack
California's marijuana industry under attackCalifornia's marijuana industry under attack
California's marijuana industry under attacknaiveinstinct1140
 
False Claims Act Focus ~ April 2013
False Claims Act Focus ~ April 2013False Claims Act Focus ~ April 2013
False Claims Act Focus ~ April 2013Patton Boggs LLP
 
The Cannabis Tech Race Is On - Leafly Sues Florida Over 3rd Party Marijuana O...
The Cannabis Tech Race Is On - Leafly Sues Florida Over 3rd Party Marijuana O...The Cannabis Tech Race Is On - Leafly Sues Florida Over 3rd Party Marijuana O...
The Cannabis Tech Race Is On - Leafly Sues Florida Over 3rd Party Marijuana O...Evergreen Buzz
 
A Computerized Business Method Is Patentable Subject Matter, N.Y.L.J., August...
A Computerized Business Method Is Patentable Subject Matter, N.Y.L.J., August...A Computerized Business Method Is Patentable Subject Matter, N.Y.L.J., August...
A Computerized Business Method Is Patentable Subject Matter, N.Y.L.J., August...Lawrence Kass
 
Conte Presentation
Conte PresentationConte Presentation
Conte PresentationKelly Savage
 
NYLJ_Drug Patents in the Spotlight
NYLJ_Drug Patents in the SpotlightNYLJ_Drug Patents in the Spotlight
NYLJ_Drug Patents in the SpotlightLawrence Kass
 
PHRMA V. WALSH 538 US 644 (2003)
PHRMA V. WALSH 538 US 644 (2003)PHRMA V. WALSH 538 US 644 (2003)
PHRMA V. WALSH 538 US 644 (2003)Andrew S. Hagler
 
American Green Rush: Business Opportunity & Risks
American Green Rush: Business Opportunity & RisksAmerican Green Rush: Business Opportunity & Risks
American Green Rush: Business Opportunity & RisksAncella Simoes
 
Senate Bill 711 to Legalize Medical Marijuana in North Carolina Goes to a Vote
Senate Bill 711 to Legalize Medical Marijuana in North Carolina Goes to a VoteSenate Bill 711 to Legalize Medical Marijuana in North Carolina Goes to a Vote
Senate Bill 711 to Legalize Medical Marijuana in North Carolina Goes to a VoteEvergreen Buzz
 

What's hot (15)

MNK Employees vs. Company 9/6/2017 Lawsuit
MNK Employees vs. Company 9/6/2017 LawsuitMNK Employees vs. Company 9/6/2017 Lawsuit
MNK Employees vs. Company 9/6/2017 Lawsuit
 
DEA Hit with Another Cannabis Lawsuit
DEA Hit with Another Cannabis LawsuitDEA Hit with Another Cannabis Lawsuit
DEA Hit with Another Cannabis Lawsuit
 
CannLabs presentation from WeedStock Investor Conference 2014
CannLabs presentation from WeedStock Investor Conference 2014CannLabs presentation from WeedStock Investor Conference 2014
CannLabs presentation from WeedStock Investor Conference 2014
 
California's marijuana industry under attack
California's marijuana industry under attackCalifornia's marijuana industry under attack
California's marijuana industry under attack
 
California's marijuana industry under attack
California's marijuana industry under attackCalifornia's marijuana industry under attack
California's marijuana industry under attack
 
Cannabis Conundrum 2018
Cannabis Conundrum 2018Cannabis Conundrum 2018
Cannabis Conundrum 2018
 
False Claims Act Focus ~ April 2013
False Claims Act Focus ~ April 2013False Claims Act Focus ~ April 2013
False Claims Act Focus ~ April 2013
 
The Cannabis Tech Race Is On - Leafly Sues Florida Over 3rd Party Marijuana O...
The Cannabis Tech Race Is On - Leafly Sues Florida Over 3rd Party Marijuana O...The Cannabis Tech Race Is On - Leafly Sues Florida Over 3rd Party Marijuana O...
The Cannabis Tech Race Is On - Leafly Sues Florida Over 3rd Party Marijuana O...
 
A Computerized Business Method Is Patentable Subject Matter, N.Y.L.J., August...
A Computerized Business Method Is Patentable Subject Matter, N.Y.L.J., August...A Computerized Business Method Is Patentable Subject Matter, N.Y.L.J., August...
A Computerized Business Method Is Patentable Subject Matter, N.Y.L.J., August...
 
GSK: Ethics Issues
GSK: Ethics IssuesGSK: Ethics Issues
GSK: Ethics Issues
 
Conte Presentation
Conte PresentationConte Presentation
Conte Presentation
 
NYLJ_Drug Patents in the Spotlight
NYLJ_Drug Patents in the SpotlightNYLJ_Drug Patents in the Spotlight
NYLJ_Drug Patents in the Spotlight
 
PHRMA V. WALSH 538 US 644 (2003)
PHRMA V. WALSH 538 US 644 (2003)PHRMA V. WALSH 538 US 644 (2003)
PHRMA V. WALSH 538 US 644 (2003)
 
American Green Rush: Business Opportunity & Risks
American Green Rush: Business Opportunity & RisksAmerican Green Rush: Business Opportunity & Risks
American Green Rush: Business Opportunity & Risks
 
Senate Bill 711 to Legalize Medical Marijuana in North Carolina Goes to a Vote
Senate Bill 711 to Legalize Medical Marijuana in North Carolina Goes to a VoteSenate Bill 711 to Legalize Medical Marijuana in North Carolina Goes to a Vote
Senate Bill 711 to Legalize Medical Marijuana in North Carolina Goes to a Vote
 

Viewers also liked

Raising Children In Islam Moral And Social Upbringing
Raising Children In Islam   Moral And Social UpbringingRaising Children In Islam   Moral And Social Upbringing
Raising Children In Islam Moral And Social Upbringingzakir2012
 
Brochure Quanam
Brochure QuanamBrochure Quanam
Brochure Quanamuikilo
 
Ciclo de comercio
Ciclo de comercioCiclo de comercio
Ciclo de comercioedymorilloc
 
Certificate in Personnel and Development Level 7
Certificate in Personnel and Development Level 7Certificate in Personnel and Development Level 7
Certificate in Personnel and Development Level 7Roger Palethorpe
 
Catalogo Productos EL EXPLORADOR
Catalogo Productos EL EXPLORADORCatalogo Productos EL EXPLORADOR
Catalogo Productos EL EXPLORADOREduardo Nortes
 
Untitled Presentation
Untitled PresentationUntitled Presentation
Untitled PresentationPIXAtokyo
 
Programa oil gas may 08 2014
Programa oil gas may 08 2014Programa oil gas may 08 2014
Programa oil gas may 08 2014Gregorio Ivanoff
 
FinalYearProjectPresentation_KlajdiHoxhaSina_Logix
FinalYearProjectPresentation_KlajdiHoxhaSina_LogixFinalYearProjectPresentation_KlajdiHoxhaSina_Logix
FinalYearProjectPresentation_KlajdiHoxhaSina_LogixKlajdi Hoxha Sina
 
Celula procariota eucariota
Celula procariota eucariotaCelula procariota eucariota
Celula procariota eucariotaLuis Montenegro
 
Whey CháMais Tecnologia de Peptídeos aplicados à sua Saúde!
Whey CháMais Tecnologia de Peptídeos aplicados à sua Saúde!Whey CháMais Tecnologia de Peptídeos aplicados à sua Saúde!
Whey CháMais Tecnologia de Peptídeos aplicados à sua Saúde!Clinic Mais
 

Viewers also liked (18)

Project Controller
Project ControllerProject Controller
Project Controller
 
Project records
Project recordsProject records
Project records
 
Raising Children In Islam Moral And Social Upbringing
Raising Children In Islam   Moral And Social UpbringingRaising Children In Islam   Moral And Social Upbringing
Raising Children In Islam Moral And Social Upbringing
 
Brochure Quanam
Brochure QuanamBrochure Quanam
Brochure Quanam
 
Ciclo de comercio
Ciclo de comercioCiclo de comercio
Ciclo de comercio
 
TS CV-16
TS CV-16TS CV-16
TS CV-16
 
Certificate in Personnel and Development Level 7
Certificate in Personnel and Development Level 7Certificate in Personnel and Development Level 7
Certificate in Personnel and Development Level 7
 
Catalogo Productos EL EXPLORADOR
Catalogo Productos EL EXPLORADORCatalogo Productos EL EXPLORADOR
Catalogo Productos EL EXPLORADOR
 
Untitled Presentation
Untitled PresentationUntitled Presentation
Untitled Presentation
 
Programa oil gas may 08 2014
Programa oil gas may 08 2014Programa oil gas may 08 2014
Programa oil gas may 08 2014
 
Likin park power
Likin park powerLikin park power
Likin park power
 
FinalYearProjectPresentation_KlajdiHoxhaSina_Logix
FinalYearProjectPresentation_KlajdiHoxhaSina_LogixFinalYearProjectPresentation_KlajdiHoxhaSina_Logix
FinalYearProjectPresentation_KlajdiHoxhaSina_Logix
 
Celula procariota eucariota
Celula procariota eucariotaCelula procariota eucariota
Celula procariota eucariota
 
Yadira
YadiraYadira
Yadira
 
Whey CháMais Tecnologia de Peptídeos aplicados à sua Saúde!
Whey CháMais Tecnologia de Peptídeos aplicados à sua Saúde!Whey CháMais Tecnologia de Peptídeos aplicados à sua Saúde!
Whey CháMais Tecnologia de Peptídeos aplicados à sua Saúde!
 
Why read?
Why read?Why read?
Why read?
 
Risk assessment
Risk assessmentRisk assessment
Risk assessment
 
Strada
StradaStrada
Strada
 

Similar to GSK's $3B Whistleblower Settlement Pays for Failed Probe

GlaxoSmithKline: GUILTY in Largest Health Fraud Settlement in US History
GlaxoSmithKline: GUILTY in Largest Health Fraud Settlement in US HistoryGlaxoSmithKline: GUILTY in Largest Health Fraud Settlement in US History
GlaxoSmithKline: GUILTY in Largest Health Fraud Settlement in US Historyfrodo2222
 
Off-Label Drug Promotion and the Use of DisclaimersfalseMcKenney,.docx
Off-Label Drug Promotion and the Use of DisclaimersfalseMcKenney,.docxOff-Label Drug Promotion and the Use of DisclaimersfalseMcKenney,.docx
Off-Label Drug Promotion and the Use of DisclaimersfalseMcKenney,.docxhopeaustin33688
 
Press Release from the U.S. Dept. of Justice on Whistleblower Case Settlement...
Press Release from the U.S. Dept. of Justice on Whistleblower Case Settlement...Press Release from the U.S. Dept. of Justice on Whistleblower Case Settlement...
Press Release from the U.S. Dept. of Justice on Whistleblower Case Settlement...Behn Wyetzner, Chartered
 
The Qui Tam Lawsuit Against Walgreens - the Federal Press Release
The Qui Tam Lawsuit Against Walgreens - the Federal Press ReleaseThe Qui Tam Lawsuit Against Walgreens - the Federal Press Release
The Qui Tam Lawsuit Against Walgreens - the Federal Press ReleaseBehn Wyetzner, Chartered
 
6. rems. the next pharmaceutical enforcement priority
6.  rems. the next pharmaceutical enforcement priority6.  rems. the next pharmaceutical enforcement priority
6. rems. the next pharmaceutical enforcement priorityMatias González Muñoz
 
FindLaw - Contraception Lawsuit Ruling
FindLaw - Contraception Lawsuit RulingFindLaw - Contraception Lawsuit Ruling
FindLaw - Contraception Lawsuit RulingLegalDocs
 
Antitrust Aspects of Acquiring a Generic Drug Manufacturer
Antitrust Aspects of Acquiring a Generic Drug ManufacturerAntitrust Aspects of Acquiring a Generic Drug Manufacturer
Antitrust Aspects of Acquiring a Generic Drug ManufacturerNexsen Pruet
 
13. 2015 mwan 010815 testimony to federal election commission 1 8-15
13.  2015 mwan 010815  testimony to federal election commission  1 8-1513.  2015 mwan 010815  testimony to federal election commission  1 8-15
13. 2015 mwan 010815 testimony to federal election commission 1 8-15MedicalWhistleblower
 
Scientists Sue the DEA over Marijuana Research, Again!
Scientists Sue the DEA over Marijuana Research, Again!Scientists Sue the DEA over Marijuana Research, Again!
Scientists Sue the DEA over Marijuana Research, Again!Evergreen Buzz
 
INHERITED SIT_BEFORE PIC-DOJ PRESS RELEASE MAXIM SETTLEMENT SEPT 2011
INHERITED SIT_BEFORE PIC-DOJ PRESS RELEASE MAXIM SETTLEMENT SEPT 2011INHERITED SIT_BEFORE PIC-DOJ PRESS RELEASE MAXIM SETTLEMENT SEPT 2011
INHERITED SIT_BEFORE PIC-DOJ PRESS RELEASE MAXIM SETTLEMENT SEPT 2011Brad Bennett
 
FTC Sues Sellers of Weight-Loss Pills for False Advertising
FTC Sues Sellers of Weight-Loss Pills for False AdvertisingFTC Sues Sellers of Weight-Loss Pills for False Advertising
FTC Sues Sellers of Weight-Loss Pills for False Advertisingmagentafluid4264
 
California fails to raise medical malpractice cap by floyd arthur
California fails to raise medical malpractice cap by floyd arthurCalifornia fails to raise medical malpractice cap by floyd arthur
California fails to raise medical malpractice cap by floyd arthurFloyd Arthur
 

Similar to GSK's $3B Whistleblower Settlement Pays for Failed Probe (20)

GlaxoSmithKline: GUILTY in Largest Health Fraud Settlement in US History
GlaxoSmithKline: GUILTY in Largest Health Fraud Settlement in US HistoryGlaxoSmithKline: GUILTY in Largest Health Fraud Settlement in US History
GlaxoSmithKline: GUILTY in Largest Health Fraud Settlement in US History
 
Off-Label Drug Promotion and the Use of DisclaimersfalseMcKenney,.docx
Off-Label Drug Promotion and the Use of DisclaimersfalseMcKenney,.docxOff-Label Drug Promotion and the Use of DisclaimersfalseMcKenney,.docx
Off-Label Drug Promotion and the Use of DisclaimersfalseMcKenney,.docx
 
Press Release from the U.S. Dept. of Justice on Whistleblower Case Settlement...
Press Release from the U.S. Dept. of Justice on Whistleblower Case Settlement...Press Release from the U.S. Dept. of Justice on Whistleblower Case Settlement...
Press Release from the U.S. Dept. of Justice on Whistleblower Case Settlement...
 
The Qui Tam Lawsuit Against Walgreens - the Federal Press Release
The Qui Tam Lawsuit Against Walgreens - the Federal Press ReleaseThe Qui Tam Lawsuit Against Walgreens - the Federal Press Release
The Qui Tam Lawsuit Against Walgreens - the Federal Press Release
 
Ethical Behaviour
Ethical BehaviourEthical Behaviour
Ethical Behaviour
 
6. rems. the next pharmaceutical enforcement priority
6.  rems. the next pharmaceutical enforcement priority6.  rems. the next pharmaceutical enforcement priority
6. rems. the next pharmaceutical enforcement priority
 
Anda Preemption
Anda PreemptionAnda Preemption
Anda Preemption
 
FindLaw - Contraception Lawsuit Ruling
FindLaw - Contraception Lawsuit RulingFindLaw - Contraception Lawsuit Ruling
FindLaw - Contraception Lawsuit Ruling
 
GlaxoSmithKline Bribery & Corruption Case
GlaxoSmithKline Bribery & Corruption CaseGlaxoSmithKline Bribery & Corruption Case
GlaxoSmithKline Bribery & Corruption Case
 
Antitrust Aspects of Acquiring a Generic Drug Manufacturer
Antitrust Aspects of Acquiring a Generic Drug ManufacturerAntitrust Aspects of Acquiring a Generic Drug Manufacturer
Antitrust Aspects of Acquiring a Generic Drug Manufacturer
 
13. 2015 mwan 010815 testimony to federal election commission 1 8-15
13.  2015 mwan 010815  testimony to federal election commission  1 8-1513.  2015 mwan 010815  testimony to federal election commission  1 8-15
13. 2015 mwan 010815 testimony to federal election commission 1 8-15
 
Chantix Writing Sample
Chantix Writing SampleChantix Writing Sample
Chantix Writing Sample
 
MedMal news
MedMal newsMedMal news
MedMal news
 
Scientists Sue the DEA over Marijuana Research, Again!
Scientists Sue the DEA over Marijuana Research, Again!Scientists Sue the DEA over Marijuana Research, Again!
Scientists Sue the DEA over Marijuana Research, Again!
 
Amazon And Pill Pack Have Options: How May A Federal Trade Commission Antitru...
Amazon And Pill Pack Have Options: How May A Federal Trade Commission Antitru...Amazon And Pill Pack Have Options: How May A Federal Trade Commission Antitru...
Amazon And Pill Pack Have Options: How May A Federal Trade Commission Antitru...
 
Cpi Article Cooper
Cpi Article CooperCpi Article Cooper
Cpi Article Cooper
 
INHERITED SIT_BEFORE PIC-DOJ PRESS RELEASE MAXIM SETTLEMENT SEPT 2011
INHERITED SIT_BEFORE PIC-DOJ PRESS RELEASE MAXIM SETTLEMENT SEPT 2011INHERITED SIT_BEFORE PIC-DOJ PRESS RELEASE MAXIM SETTLEMENT SEPT 2011
INHERITED SIT_BEFORE PIC-DOJ PRESS RELEASE MAXIM SETTLEMENT SEPT 2011
 
FTC Sues Sellers of Weight-Loss Pills for False Advertising
FTC Sues Sellers of Weight-Loss Pills for False AdvertisingFTC Sues Sellers of Weight-Loss Pills for False Advertising
FTC Sues Sellers of Weight-Loss Pills for False Advertising
 
California fails to raise medical malpractice cap by floyd arthur
California fails to raise medical malpractice cap by floyd arthurCalifornia fails to raise medical malpractice cap by floyd arthur
California fails to raise medical malpractice cap by floyd arthur
 
Natures Answer
Natures AnswerNatures Answer
Natures Answer
 

GSK's $3B Whistleblower Settlement Pays for Failed Probe

  • 1. GlaxoSmithKline's (GSK) $3 Billion Whistleblower Settlement Has Paid for One Of America's Most Expensive Failed Corporate Internal Investigations, Qui Tam Whistleblowers' Attorneys Say. The original Complaint is one of the first ever filed alleging prescription drug off-label promotion, Kenney said. When the whistleblowers' Complaints were still under seal and being investigated by the government GSK allegedly falsified and concealed documents in connection with an FDA inquiry into whether GSK marketed the antidepressant drug Wellbutrin off-label for weight loss, a central allegation in the whistleblowers' Complaints. Massachusetts Assistant Attorney General Bob Patten led the investigation on behalf of the states and the National Association of Medicaid Fraud Control Units ("NAMFCU"). Case Caption: United States ex rel. Generally, government-funded healthcare programs such as Medicare and Medicaid preclude reimbursement for off-label prescriptions. Department of Justice, and the U.S. An ensuing GSK internal investigation verified their allegations, but the company took no action, choosing hefty profits over compliance and patient safety," said whistleblower attorney Tavy Deming of Kenney McCafferty. "GSK could have saved hundreds of millions, perhaps a billion or more dollars of the $3 billion it paid today by following through on the combined Human Resources /Corporate Compliance investigation they launched. As a result,
  • 2. Advair's portion of taxpayers' recovery represents nearly 70 percent of the Government's total $1.017 billion civil settlement of our clients' claims, Lambert added. The nine prescription drugs covered by the settlement included Advair, Wellbutrin, Paxil, Lamictal, Zofran, Imitrex, Lotronex, Flovent and Valtrex. GSK maintained an elaborate illegal marketing regime for the prescription drugs included in today's settlement, including, according to filed documents: * Paying physicians (who could be counted on to influence their peers) as much as $25,000 for being a GSK "advisory board" member; * Enrolling 49,000 physicians and health professionals to be part of its speakers bureau; * Identifying physicians in academia to pay to speak on behalf of one of the company's drugs; * Creating the PowerPoint "slide kits" that physicians would use to deliver canned presentations; * Using an elaborate "FaxBack" system allowing drug marketing reps to suggest articles related to off-label uses. No.: 11-10398 (D.Mass) About Kenney McCafferty, P.C.: Kenney McCafferty, P.C. is the one of the most successful national law firms specializing in representing qui tam, tax, and SEC whistleblowers. When the two Kenney McCafferty-represented whistleblowers reported their concerns about illegal marketing practices they were witnessing in the
  • 3. field, GSK's top compliance executive, an attorney who now holds a similar position with another medical device manufacturer, became involved in and oversaw the ensuing internal investigation. Instead of changing the illegal conduct, the Company retaliated against the whistleblowers and they became the first to file an off-label marketing qui tam whistleblower Complaint against GSK. Federal laws also prohibit pharmaceutical companies from paying kickbacks to physicians to induce prescriptions. "It's been a very, very, very long 10 years for whistleblowers Thorpe and Blair Hamrick." GSK's top management was aware of illegal marketing schemes involving the drugs, according to filed court documents. (U.S. In turn, as is typical in civil agreements, GSK expressly denied liability, except for those admissions GSK agreed to make in connection with connection with a criminal Plea Agreement. v. Our clients properly reported those marketing misdeeds to management in 2001. The physicians would order these -off-label promotional materials by calling a toll-free number, and thus not appear to be responding to an illegal marketing effort by the drug marketing representative; * Pushing Imitrex, an adult medicine for migraine, for mild headaches, as well as for use in children, despite the FDA's
  • 4. rejection of GSK's application for child use due to lack of efficacy; * Pushing Lamictal, a drug approved only for partial seizures, in adults for other diagnoses. Instead they ignored evidence of improper marketing and physician kickbacks. In at least one case a patient died from a reaction that the company had evidence could occur; * Marketing Paxil, the antidepressant, to children under 18 when it had not been approved for youngsters, and despite GSK's own clinical trails that had shown that the drug was ineffective for children and also heightened the risk of suicide or other self-harming behavior three-fold; and, * Marketing the antidepressant Wellbutrin as superior to other antidepressant alternatives due to increased sexual functioning and weight loss, pushing the drug as the "happy, horny, skinny drug," to concisely encapsulate GSK's off-label Wellbutrin marketing campaign. Physicians are free to prescribe drugs for off-label uses, but pharmaceutical companies are prohibited from marketing the drugs for uses that have not been approved by the FDA. Lauren Stevens, District of Maryland) Thorpe and Hamrick provided first-hand revelations of GSK's pervasive marketing misconduct relating to the nine drugs identified in Kenney McCafferty's Complaint (See "Document Links" Below) and Exhibits (See "Document Links" Below) unsealed with today's settlement. Kenney McCafferty's qui tam lawsuits have resulted in cases in which more than $5 billion in civil and criminal
  • 5. fines and penalties have been recovered for federal and state Governments, resulting in the payment of hundreds of millions of dollars in whistleblower rewards. Contacts: Kenney McCafferty, P.C. 215-367-4333 Brian Kenney bkenney@kenneymccafferty.com Tavy Deming tdeming@kenneymccafferty.com. Additional information about the firm is available at http://www.quitam-lawyer.com and http://www.tax-fraud.net. Document Links: Call the attorneys to obtain at-once copies of these documents. For not-breaking access, as they become available, filed documents can be accessed via the "GSK" link on the quitam-lawyer.com homepage "Cases Over $100 Million." SOURCE Kenney McCafferty, P.C. COPYRIGHT 2012 PR Newswire Association LLC No portion of this article can be reproduced without the express written permission from the copyright holder. Copyright 2012 Gale, Cengage Learning. All rights reserved. . When you look at the detail and accuracy of Greg Thorpe's written complaints distributed to the highest levels of Glaxo (See 'Document Links' Below) it's almost surreal that the company took no corrective action. Now more than a decade later, GSK is essentially admitting that Thorpe had been right in
  • 6. 2001," Kenney said. That led to the indictment of a GSK associate corporate counsel, said Deming. Federal charges against the former associate general counsel later were subsequently dismissed by the court. His law firm, Kenny McCafferty, P.C., represents the two whistleblowers who sparked the nine-year federal probe that ended with today's $3 billion payment to settle off-label drug marketing allegations involving nine prescription drugs. "When our clients were forced out of their marketing positions, GlaxoSmithKline ('GSK') had proof of illegal off-label prescription drug marketing. The FCA allows the Government to collect up to three times the amount it was defrauded, in addition to civil penalties from $5,500 to $11,000 per false claim. In successful qui tam whistleblower cases in which the Government intervenes, whistleblowers are entitled to receive a percentage of qui tam recoveries, typically 15-to-25 percent, generally known as, "the relator's share." Under the terms of the settlement agreement, the Government and the whistleblowers did not http://www.schmidtlaw.com/zofran-lawsuits/ concede that their respective claims are not well founded. (See "Document Links" Below) Extremely persuasive proof exposing illegal marketing of the asthma drug Advair for mild asthma was included in the insider evidence that Thorpe and Hamrick provided to Government investigators, Deming said. GSK's mild asthma marketing campaign contravened Advair's approved asthma use, which was limited to moderate and severe forms of asthma, and a black box warning on the zofran birth defects heart drug's label, yet GSK's
  • 7. marketing efforts continued unabated into 2010. v. According to Emily Lambert of Kenney McCafferty, the Government joined the whistleblowers' case and filed a Complaint-in-Intervention adopting the whistleblower's claims. Attorney's Offices for the District of Massachusetts and the District of Colorado. Thorpe, et al. When a pharmaceutical company's illegal marketing practices cause off-label prescriptions to be written by doctors, and those prescriptions are paid for by Medicare and Medicaid, the payment becomes an actionable False Claims Act ("FCA") violation, according to Kenney, who is a former federal prosecutor. Under the FCA, qui tam actions allow private citizens with knowledge of fraud to help the Government recover ill-gotten gains and additional civil penalties. Specifically, according to the agreement, GSK has agreed to plead guilty to criminal charges that the company misbranded Wellbutrin and Paxil and it failed to report data relating to clinical experience, along with other data and information regarding the diabetes drug Avandia to the Food and Drug Administration ("FDA") in mandatory reports, all in violation of the Food, Drug and Cosmetic Act ("FDCA"). In addition to paying a $1.042 billion civil settlement to the federal and state Governments, as part of the Settlement Agreement GSK agreed to be bound by a Corporate Integrity Agreement ("CIA") with the Office of Inspector General of the United States Department of Health and Human Services ("OIG-HHS"). The federal investigation into GSK's marketing practices was conducted through a collaborative effort of the U.S.
  • 8. PHILADELPHIA, July 2, 2012 /PRNewswire/ -- GlaxoSmithKline has just paid for one of the most expensive failed internal investigations in corporate history, qui tam whistleblower attorney Brian Kenney said today. GSK, et al.Civ